**Title: A diet-dependent enzyme from the human gut microbiome promotes
Th17 cell accumulation and colitis**

Authors: Margaret Alexander¹, Qi Yan Ang¹, Renuka R. Nayak^{1,2}, Annamarie E. Bustion¹,
Vaibhav Upadhyay^{1,3}, Katherine S. Pollard^{1,4}, and Peter J. Turnbaugh^{1,4*}

Affiliations:

¹Department of Microbiology & Immunology, University of California San Francisco, CA 94143,
USA

²Rheumatology Division, Department of Medicine, University of California, San Francisco, CA
94158, USA

³Department of Medicine, University of California, San Francisco, CA 94158, USA

⁴Chan Zuckerberg Biohub, San Francisco, CA 94158, USA

*Correspondence to: Peter.Turnbaugh@ucsf.edu

Abstract:

Aberrant activation of Th17 cells by the gut microbiota contributes to autoimmunity; however, the mechanisms responsible and their diet-dependence remain unclear. Here, we show that the autoimmune disease-associated gut Actinobacterium *Eggerthella lenta* increases intestinal Th17 cells and worsens colitis in a *Rorc*-dependent and strain-variable manner. A single genomic locus predicted Th17 accumulation. A gene within this locus, encoding the Cgr2 enzyme, was sufficient to increase Th17 cells. Levels of *cgr2* were increased in stool from patients with rheumatoid arthritis compared to healthy controls. Dietary arginine blocked *E. lenta*-induced Th17 cells and colitis. These results expand the mechanisms through which bacteria shape mucosal immunity and demonstrate the feasibility of dissecting the complex interactions between diet, the gut microbiota, and autoimmune disease.

One Sentence Summary: An autoimmune disease-associated bacterium triggers disease due to a diet-dependent enzyme that regulates mucosal immunity.

Main Text:

Intestinal immune responses are linked to the trillions of microorganisms that colonize the gastrointestinal tract (1, 2). Therefore, inter-individual variations in the gut microbiome could contribute to diseases associated with dysregulated immune responses such as autoimmunity (3–5). Consistent with this hypothesis, multiple disease models are ameliorated in germ-free (GF) or antibiotic-treated mice (6–8). Microbiome-wide association studies have identified bacteria enriched in autoimmune diseases, including rheumatoid arthritis (RA) (3), inflammatory bowel disease (IBD) (4), and multiple sclerosis (5, 9). However, whether or not these human gut bacterial strains play a causal role in disease remains largely unknown. Furthermore, the observation that host diet significantly impacts the structure and function of the gut microbiome (10–12) raises the question of whether or not diet-mediated shifts in the microbiome impact bacterial immune modulation and downstream disease phenotypes.

The mechanisms whereby the gut microbiome influences autoimmune disease and the role of diet in these interactions are even more mysterious. Perhaps the most well-studied mechanism is the bacterial-induced accumulation of T helper 17 (Th17) cells which are involved in maintaining the intestinal barrier and coordinating immune responses to extracellular pathogens and whose aberrant activation drives autoimmunity (13). Seminal work revealed that segmented filamentous bacteria (SFB) increase CD4⁺ IL-17a⁺ Th17 cells in mice (14, 15). Likewise, the composition and structure of the human gut microbial community significantly impact Th17 levels and severity of disease models following transfer into germ-free mice (15, 16). The prevalent human gut Actinobacterium *Bifidobacterium adolescentis*, which is enriched in IBD patients (17), also increases CD4⁺ IL-17a⁺ Th17 cells and worsens arthritis in a mouse model (18). Similar to SFB, the physical adhesion of *B. adolescentis* to the intestinal epithelium has been implicated in

the mechanism of Th17 accumulation; however, it remains unclear if other gut bacterial species regulate Th17 cells through adhesion-independent mechanisms.

Eggerthella lenta, another prevalent gut Actinobacterium found in >80% of individuals (19), is enriched and coated with IgA in patients with autoimmune diseases (3, 5, 20), but the impact of this bacterium on host immunity and disease phenotypes remains unexplored. Here, we show that *E. lenta* colonization is sufficient to increase intestinal CD4⁺ IL-17a⁺ (Th17) cell levels and exacerbates murine colitis. Through a combination of gnotobiotics, comparative genomics, *in vitro* assays, and bacterial genetics we identify a single strain-variable gene (cardiac glycoside reductase 2, *cgr2*) which is sufficient to increase Th17 cells. These data provide the first physiological function for Cgr2, which was previously implicated in xenobiotic metabolism, inactivating the cardiac drug digoxin and other toxic plant compounds within the cardenolide family (12, 21). *Cgr2* copy number is significantly higher in RA patient stool samples than healthy controls, supporting the translational relevance of these findings. Finally, by leveraging the knowledge that Cgr2 activity is abrogated by high levels of dietary arginine (12, 21) we show that dietary arginine prevents *E. lenta*-dependent Th17 accumulation and associated colitis emphasizing that diet can affect the capacity of specific bacterial strains to modulate immune responses and downstream disease.

E. lenta colonization of germ-free (GF) mice increases Th17 activation. GF mice colonized with *E. lenta* strain UCSF 2243 for two weeks had increased percentages of IL-17a⁺ CD4⁺ (Th17) cells within the CD3⁺ population in the small intestine and colon but not spleen (Figs. 1A-F, fig. S1A-B). Increases in IL-17a⁺ CD4⁺ percentages were accompanied by increased IL-17a mean fluorescence intensity (MFI) in the small intestine and colon (Figs. 1C and F). However, levels of CD4⁺ Rorγt⁺ cells and Rorγt MFI were not altered in *E. lenta* colonized mice in any of these

tissues compared to GF mice (Figs. 1G-L, figs. S1C-D). *E. lenta* monocolonization did not have a significant effect on intestinal IFN γ ⁺ CD4⁺ T cells, IL17a⁺ TCR γ δ ⁺ T cells, or lineage- Ror γ t⁺ IL-17a⁺ group 3 innate lymphoid cells (ILC3) compared to GF mice (figs. S1E-L). However, while lineage- Ror γ t⁺ IL-22⁺ cells were decreased in *E. lenta* monocolonized mice, total IL-22 MFI was not altered in *E. lenta* monocolonized mice, suggesting that IL-22 producing ILC3 cells are decreased in *E. lenta* monocolonized mice but total expression of IL-22 is not changed (figs. S1K, and S1M-N). qPCR of GF and *E. lenta* monocolonized mice ileal tissue revealed an increase in Ror γ t targets IL-17f, CCR6, a trending increase in IL-23r, but no significant differences in IL-22 and Ror γ t levels (Fig. 1M). There were no significant changes in Th1 associated transcripts (IFN γ , Tbet), Treg associated transcript (FoxP3), or other inflammatory markers, with the exception of a trend towards increased BCL6, which could indicate an increase in T follicular helper cells (Fig. 1M and fig. S1O). To test if *E. lenta* promotes IL-17a⁺ CD4⁺ accumulation in the context of a more complex microbiota, we gavaged SPF mice with *E. lenta* or a media control (BHI) every other day for two weeks and observed a similar accumulation of IL-17a⁺ CD4⁺ cells in the small intestinal and colonic lamina propria and increased IL-17a MFI with *E. lenta* (Fig. 1N-S). We observed a similar pattern in the CD4⁺ IL-17f⁺ population and IL-17f MFI but again no significant differences in the CD4⁺ Ror γ t⁺ population (figs. S2A-H). We further tested whether secreted factors from *E. lenta* were sufficient to promote Th17 accumulation by gavaging SPF mice with conditioned media from *E. lenta* or a BHI control and observed a similar increase in CD4⁺ IL-17a⁺ cells, IL-17a MFI, and IL-17f MFI in the small intestine (figs. S2I-L).

Prior studies have found *E. lenta* at higher levels in patients with rheumatoid arthritis (3) and multiple sclerosis (5, 9) relative to healthy controls, suggesting a general association between this bacterial species and autoimmune disease. To assess the broader relevance of *E. lenta* in

human autoimmune disease, we analyzed two metagenomic datasets totaling 105 IBD patients (52 ulcerative colitis and 53 Crohn's disease) and 100 healthy subjects (22–24). A combined analysis revealed that *E. lenta* was significantly higher in IBD patient stool samples relative to healthy controls (figs. S4A-F). These results indicate that there may be a general mechanism linking *E. lenta* to multiple autoimmune diseases.

Next, we turned to mouse models of IBD due to the ability to readily use these models in a gnotobiotic system and associations with *E. lenta* levels, allowing us to test the impact of *E. lenta* colonization on the severity of autoimmune disease phenotypes. GF mice were colonized 2 weeks with *E. lenta* prior to DSS colitis induction to assess the impact of Th17 activation on disease phenotypes. *E. lenta* colonized mice developed more severe disease than their GF counterparts in both disease scores and colon shortening, crypt destruction as observed via histology, elevated lipocalin levels, and increased colonic Th17 levels (Figs. 2A-D and figs. S5A-D). To determine if *E. lenta* mediated Th17 accumulation contributed to this worsened disease phenotype, we compared *WT* and *Rorc*^{-/-} SPF mice gavaged with *E. lenta* or BHI media control every other day for 2 weeks preceding induction of DSS colitis. *E. lenta* colonized *WT* SPF mice developed more severe disease compared to BHI controls while *Rorc*^{-/-} mice had no differences in disease severity between the BHI and *E. lenta* groups (Figs. 2E-H). Th17 levels were elevated in the colon of *WT* mice gavaged with *E. lenta* but, as expected, there were low levels of these cells and no difference between *E. lenta* gavage and control in the *Rorc*^{-/-} mice (figs. S5E-H). These results suggest that Th17 accumulation by *E. lenta* contributes to worsened colitis severity in *E. lenta* colonized mice, although it is important to note that Th17 cells are not the only cell type missing from *Rorc*^{-/-} mice as ILC3 cells are also lacking and these mice additionally have issues with thymopoiesis (25). To test whether *E. lenta* colonization contributes to more severe disease in an independent model of

colitis, we gavaged *E. lenta* or a media control (BHI) three times a week into *IL-10*^{-/-} SPF mice and tracked weights and survival. *E. lenta* gavage resulted in lower percentage of initial weight, decreased survival, and increased lipocalin compared to the media control (Figs. 2I-K) suggesting that *E. lenta* colonization contributes to more severe disease in a chronic colitis model.

E. lenta mediated Th17 accumulation is a strain-variable phenotype. We monocolonized mice with *E. lenta* strains UCSF 2243 (2243), FAA 1-3-56 (1356), DSM 15644 (15644), AB12#2 (AB12), or heat-killed *E. lenta* 2243 (see table S1 for strain information). Viable *E. lenta* 2243 and AB12 were the only groups which elevated Th17 levels compared to GF mice in intestinal compartments (Figs. 3A-D and figs. S6A-C) indicating *E. lenta* mediated Th17 accumulation is strain variable and requires live bacteria. Interestingly, the AB12 strain promoted Th17 accumulation to a greater extent in the colon than the small intestine compared to the 2243 strain which promoted Th17 accumulation in both the small intestine and colon. Next, we tested whether monocolonization with a strain of *E. lenta* that did not increase Th17 levels would impact DSS colitis. While monocolonization with *E. lenta* 2243 caused more severe colitis, colonization with *E. lenta* 1356 did not, as observed with lower disease scores, less severe colon shortening, lower colon lipocalin levels, and fewer intestinal Th17 cells (Figs. 3E-G, fig. S6D-F).

To assess the variation between *E. lenta* strains and their capacity to increase Th17 cells, we turned to an *in vitro* cell culture assay. Splenic CD4⁺ T cells were cultured in Th17 skewing conditions with the addition of conditioned media from *E. lenta* strains or media controls. Recapitulating our *in vivo* findings, conditioned media from *E. lenta* 2243 but not 1356 or 15644 significantly increased IL-17a levels compared to media control as assessed by IL-17a ELISA (Fig. 4A). Of note, unconditioned media (BHI) decreased IL-17a production, suggesting there is a factor in our bacterial culture media inhibiting its production. With our *in vitro* system, we wanted

to further characterize the mechanism by which *E. lenta* strain 2243 conditioned media alters IL-17a levels. Heat treatment or filtering through a 3 kDa filter did not abrogate the IL-17a inducing activity of *E. lenta* strain 2243 conditioned media compared to BHI controls (fig. S7A) suggesting a small molecule is involved in IL-17a induction in our *in vitro* setting. Further, we assessed whether the conditioned media was changing Th17 differentiation, proliferation, or expression of IL-17a by altering the timing of conditioned media addition (fig. S7B). *E. lenta* strain 2243 conditioned media resulted in higher IL-17a levels compared to controls whether added at the time of Th17 skewing or after skewing had already occurred (figs. S7C and 7D). However, proliferation levels were not different between conditions (figs. S7E and 7F). These results suggest that the 2243 conditioned media can impact IL-17a production after cells have been differentiated, which supports a mechanism where *E. lenta* 2243 acts upon IL-17a production, not Th17 proliferation.

Having validated our *in vitro* assay, we tested a broader panel of 10 *E. lenta* strains (19) for their IL-17a induction capacity. This screen revealed 6 *E. lenta* strains that did not increase IL-17a production and 4 strains that significantly increased IL-17a production (Fig. 4B). Using the ElenMatchR comparative genomics tool (19), we determined that a single genomic locus (orthologous gene cluster 2770-2839), was present in all of the strains that increased IL-17a production and missing from all of the strains that did not induce IL-17a (Fig. 4B, figs. S8B-D). We had previously implicated this same locus, referred to as the cardiac glycoside reductase (*cgr*)-associated gene cluster, in the metabolism of the cardiac drug digoxin and other plant toxins from the cardenolide family (21). These results indicated that one or more of the genes in this locus also plays a role in shaping host immunity.

Based on prior evidence that digoxin inhibits Th17 cell differentiation (26, 27), we hypothesized that the enzyme sufficient for digoxin reduction, Cgr2, may be capable of increasing

Th17 cells due to the reduction of an endogenous substrate found in the mouse gut lumen and our BHI cell culture media. A key prediction of this hypothesis is that Cgr2 should be sufficient to promote IL-17a production in our *in vitro* assay. We used constructs in which WT *cgr2* or a partial loss-of-function natural variant of *cgr2* (Y333N) were expressed in *Rhodococcus erythropolis* under control of a thiostrepton-inducible promoter (21). Expression of the WT but not variant form of *cgr2* resulted in a significant increase in IL-17a levels compared to uninduced controls (Fig. 4C). To confirm that *cgr2* expression is also sufficient to increase Th17 cells *in vivo*, we supplied SPF mice with conditioned media from *R. erythropolis* strains with WT or Y333N *cgr2* in the presence or absence of the thiostrepton inducer. Conditioned media from *R. erythropolis* with induced WT *cgr2* expression resulted in a significant increase in small intestinal Th17 cells compared (Fig. 4D and 4E). The partial loss of function mutant Y333N displayed an intermediate phenotype where Th17 levels were increased compared to uninduced controls but to a lesser magnitude than the WT *cgr2* version (figs. S8E-G).

Due to our findings that *cgr2* is sufficient to induce Th17 cells we postulated that the *cgr2* gene locus may be associated with Th17 driven diseases such as rheumatoid arthritis (RA). We analyzed the levels of *cgr2* via qPCR from the stool of patients with RA before any therapeutic intervention and healthy controls and found that *cgr2* levels were significantly increased in RA patient stool; 83% (10/12) of the RA patient samples had detectable *cgr2* compared to 54% (6/11) in healthy controls (Fig. 4F-G; $p < 0.05$, one-sided Fisher's exact test). These results provide initial support for the translational relevance of this specific bacterial gene for human autoimmune diseases.

Prior studies have shown that elevated protein intake, likely due to the increased concentration of arginine in the gut lumen, inhibits the ability of Cgr2 to reduce the cardiac drug

digoxin (12, 21). We hypothesized that arginine would have a similar ability to prevent *E. lenta* mediated Th17 accumulation and associated disease phenotypes. GF, *E. lenta* strain 2243 (a *cgr*⁺ strain), or 15644 (a *cgr*⁻ strain) monocolonized mice were fed a 1% or 3% arginine diet. *E. lenta* 2243 colonized mice had elevated Th17 cells on the 1% arginine diet, but those levels were decreased back to baseline levels on the 3% arginine diet (Figs. 5A and 5B), and the different levels of Arg did not have a significant impact on the level of *E. lenta* colonization (fig. S9A). Consistent with our hypothesis, Th17 cells were significantly decreased on 3% arginine diet in *cgr*⁺ 2243, whereas the opposite was seen in *cgr*⁻ 15644 although to a lesser magnitude than the effect of strain 2243 (figs. S9C-D). There was no impact of arginine levels in GF mice (fig. S9B). As an additional control, we monocolonized mice on a 1% or 3% arginine diet with *Bifidobacterium adolescentis*, which has been shown to induce Th17 cells (18). *B. adolescentis* BD1 showed a similar response to arginine as *E. lenta* strain 15644, where the 3% arginine diet condition had trending higher levels of Th17 cells compared to the 1% arginine diet (fig. S9E). These results suggest that dietary arginine can have opposing effects on Th17 cells depending on gut bacterial colonization; higher arginine decreases Th17 levels in the context of *E. lenta* strain 2243 colonization but increases Th17 levels in mice colonized with *E. lenta* strain 15644 or *B. adolescentis*. To determine if the effect of arginine levels on *E. lenta* mediated Th17 accumulation alters colitis outcome, we gavaged *E. lenta* 2243 (*cgr*⁺), or 15644 (*cgr*⁻) into SPF mice on a 1% or 3% arginine diet every other day for two weeks and then induced DSS colitis. Mice gavaged with *E. lenta* 2243 (*cgr*⁺) on a high arginine diet had decreased Th17 cells and reduced disease severity compared to those on a low arginine diet (Figs. 5C-G). Differing arginine levels had no significant effects on disease severity or Th17 levels in the BHI or *E. lenta* strain 15644 (*cgr*⁻) treated groups (Figs. 5C-G). These results demonstrate that, in the context of colonization with a

cgr+ *E. lenta* strain, increased arginine in the diet decreases both Th17 accumulation and colitis severity.

The immunomodulatory effects of members of the human gut microbiota have long been appreciated and the microbiome field is now making efforts to explore the variety of mechanisms whereby these microbes influence a host's immune response. Previous studies have identified bacteria capable of increasing Th17 levels and have implicated bacterial adherence to the gut epithelial in this activation (15, 18, 28). While we do not rule out that *E. lenta* can promote Th17 accumulation through an epithelial adhesion mechanism our results demonstrate that colonization is not necessary as conditioned media gavage is sufficient to induce intestinal Th17 cells. However, it is entirely possible that a single bacterium could increase Th17 cells through multiple mechanisms, as seen with SFB (15, 29). With recent studies profiling the immunomodulatory properties of a range of microbes spanning multiple phyla (18, 30), we have gained insight into how these associations could be leveraged for therapy (31). However, it is important to note that we may be missing many microbe-immune interactions due to the strain-level differences in immune modulation. For example, rat-derived SFB does not increase Th17 cells in mice, but mouse-derived SFB does (15). This concept also applies to bifidobacteria where *B. infantis* monocolonization increases Th17 cells but *B. longum* monocolonization does not (18); *B. infantis* is a subspecies of *B. longum*. These observations emphasize that strain-level variations have significant effects on host immune responses, and the current study outlines a generalizable strategy to determine the genes responsible. An important future area of study will be to investigate whether colonization with multiple inducers of Th17 cells results in a combinatorial effect on Th17 levels as this could inform as to whether these bacteria are inducing Th17 via similar or disparate mechanisms.

Cgr2 has been previously studied for its role in reducing the heart medication digoxin into a less active by-product, dihydrodigoxin (12). Digoxin is also a potent Th17 inhibitor and binds directly to the master transcription factor of Th17 cells, Ror γ t (26, 27) while dihydrodigoxin is a less potent inhibitor (32). Yet digoxin is not normally present in the gastrointestinal tract and so the question arises whether Cgr2 is acting on another endogenous substrate. The substrate specificity of Cgr2 was recently explored and suggested that Cgr2 acts exclusively on the cardenolide class of molecules (21). Our working hypothesis is that Cgr2 acts on an endogenous Th17 inhibitory compound present both in mice and our BHI media that resembles digoxin (33) (fig. S10). Consistent with this hypothesis, a bile acid metabolite can inhibit Th17 cells by directly binding to Ror γ t (34) and the levels of CD4⁺ IL-17a⁺ T cells and the MFI of Ror γ t targets IL-17a and IL-17f were increased in *E. lenta* strain 2243 colonized mice but levels of Ror γ t MFI and CD4⁺ Ror γ t⁺ T cells were not. These findings suggest that *E. lenta* strain 2243 colonization may act by dampening the transcriptional regulation of Ror γ t.

Diet is a key environmental factor that shapes the microbiota and microbial-mediated immune modulation. However, it is often difficult to assess the direct impact of dietary alterations on immune diseases from microbiota-mediated effects as a dietary alteration could have a range of effects directly on the host and microbiota that act in a synergistic or opposing fashion. Dietary arginine has multiple reported effects on mammalian cells (35), including iNOS-dependent suppression of inflammation (36), macrophage-dependent shifts in regulatory versus inflammatory skewing (35, 37), and T cell proliferation and cytokine production (38, 39). There are also multiple potential mechanisms through which arginine may interact with the gut microbiota, including diet-dependent shifts in gut microbial community structure and function (10, 11) or the microbial metabolism of arginine into polyamides (40), which have immunomodulatory functions and can

alter microbial metabolism (12). Our results further emphasize that the effects of arginine on host phenotype is both concentration- and microbiome-dependent and provide a tractable model to continue to dissect the complex mechanisms that link dietary amino acids, the gut microbiota, and autoimmune disease.

References and Notes:

1. Y. Belkaid, T. W. Hand, Role of the microbiota in immunity and inflammation. *Cell*. **157**, 121–141 (2014).
2. L. V. Hooper, D. R. Littman, A. J. Macpherson, Interactions between the microbiota and the immune system. *Science*. **336**, 1268–1273 (2012).
3. X. Zhang, D. Zhang, H. Jia, Q. Feng, D. Wang, D. Liang, X. Wu, J. Li, L. Tang, Y. Li, Z. Lan, B. Chen, Y. Li, H. Zhong, H. Xie, Z. Jie, W. Chen, S. Tang, X. Xu, X. Wang, X. Cai, S. Liu, Y. Xia, J. Li, X. Qiao, J. Y. Al-Aama, H. Chen, L. Wang, Q.-J. Wu, F. Zhang, W. Zheng, Y. Li, M. Zhang, G. Luo, W. Xue, L. Xiao, J. Li, W. Chen, X. Xu, Y. Yin, H. Yang, J. Wang, K. Kristiansen, L. Liu, T. Li, Q. Huang, Y. Li, J. Wang, The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat. Med.* **21**, 895–905 (2015).
4. D. N. Frank, A. L. St Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, N. R. Pace, Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 13780–13785 (2007).
5. E. Cekanaviciute, B. B. Yoo, T. F. Runia, J. W. Debelius, S. Singh, C. A. Nelson, R. Kanner, Y. Bencosme, Y. K. Lee, S. L. Hauser, E. Crabtree-Hartman, I. K. Sand, M. Gacias, Y. Zhu, P. Casaccia, B. A. C. Cree, R. Knight, S. K. Mazmanian, S. E. Baranzini, Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 10713–10718 (2017).
6. Y. K. Lee, J. S. Menezes, Y. Umesaki, S. K. Mazmanian, Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. U. S. A.* **108 Suppl 1**, 4615–4622 (2011).
7. Y. Maeda, T. Kurakawa, E. Umemoto, D. Motooka, Y. Ito, K. Gotoh, K. Hirota, M. Matsushita, Y. Furuta, M. Narazaki, N. Sakaguchi, H. Kayama, S. Nakamura, T. Iida, Y. Saeki, A. Kumanogoh, S. Sakaguchi, K. Takeda, Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. *Arthritis Rheumatol.* **68**, 2646–2661 (2016).
8. H. Yokote, S. Miyake, J. L. Croxford, S. Oki, H. Mizusawa, T. Yamamura, NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. *Am. J.*

- 1 *Pathol.* **173**, 1714–1723 (2008).
- 2 9. A.-K. Pröbstel, S. E. Baranzini, The Role of the Gut Microbiome in Multiple Sclerosis Risk
3 and Progression: Towards Characterization of the “MS Microbiome.” *Neurotherapeutics*.
4 **15**, 126–134 (2018).
- 5 10. L. A. David, C. F. Maurice, R. N. Carmody, D. B. Gootenberg, J. E. Button, B. E. Wolfe,
6 A. V. Ling, A. S. Devlin, Y. Varma, M. A. Fischbach, S. B. Biddinger, R. J. Dutton, P. J.
7 Turnbaugh, Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. **505**,
8 559–563 (2014).
- 9 11. P. J. Turnbaugh, V. K. Ridaura, J. J. Faith, F. E. Rey, R. Knight, J. I. Gordon, The effect of
10 diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice.
11 *Sci. Transl. Med.* **1**, 6ra14 (2009).
- 12 12. H. J. Haiser, D. B. Gootenberg, K. Chatman, G. Sirasani, E. P. Balskus, P. J. Turnbaugh,
13 Predicting and manipulating cardiac drug inactivation by the human gut bacterium
14 *Escherichia coli*. *Science*. **341**, 295–298 (2013).
- 15 13. J. Yang, M. S. Sundrud, J. Skepner, T. Yamagata, Targeting Th17 cells in autoimmune
16 diseases. *Trends Pharmacol. Sci.* **35**, 493–500 (2014).
- 17 14. I. I. Ivanov, K. Atarashi, N. Manel, E. L. Brodie, T. Shima, U. Karaoz, D. Wei, K. C.
18 Goldfarb, C. A. Santee, S. V. Lynch, T. Tanoue, A. Imaoka, K. Itoh, K. Takeda, Y.
19 Umesaki, K. Honda, D. R. Littman, Induction of intestinal Th17 cells by segmented
20 filamentous bacteria. *Cell*. **139**, 485–498 (2009).
- 21 15. K. Atarashi, T. Tanoue, M. Ando, N. Kamada, Y. Nagano, S. Narushima, W. Suda, A.
22 Imaoka, H. Setoyama, T. Nagamori, E. Ishikawa, T. Shima, T. Hara, S. Kado, T. Jinnohara,
23 H. Ohno, T. Kondo, K. Toyooka, E. Watanabe, S.-I. Yokoyama, S. Tokoro, H. Mori, Y.
24 Noguchi, H. Morita, I. I. Ivanov, T. Sugiyama, G. Nuñez, J. G. Camp, M. Hattori, Y.
25 Umesaki, K. Honda, Th17 cell induction by adhesion of microbes to intestinal epithelial
26 cells. *Cell*. **163**, 367–380 (2015).
- 27 16. G. J. Britton, E. J. Contijoch, I. Mogno, O. H. Vennaro, S. R. Llewellyn, R. Ng, Z. Li, A.
28 Mortha, M. Merad, A. Das, D. Gevers, D. P. B. McGovern, N. Singh, J. Braun, J. P. Jacobs,
29 J. C. Clemente, A. Grinspan, B. E. Sands, J.-F. Colombel, M. C. Dubinsky, J. J. Faith,
30 Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17
31 and ROR γ t⁺ regulatory T cells and exacerbate colitis in mice. *Immunity*. **50**, 212–224.e4
32 (2019).
- 33 17. S. Nayfach, M. A. Fischbach, K. S. Pollard, MetaQuery: a web server for rapid annotation
34 and quantitative analysis of specific genes in the human gut microbiome. *Bioinformatics*.
35 **31**, 3368–3370 (2015).
- 36 18. T. G. Tan, E. Sefik, N. Geva-Zatorsky, L. Kua, D. Naskar, F. Teng, L. Pasman, A. Ortiz-
37 Lopez, R. Jupp, H.-J. J. Wu, D. L. Kasper, C. Benoist, D. Mathis, Identifying species of
38 symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice.

- 1 *Proc. Natl. Acad. Sci. U. S. A.* **113**, E8141–E8150 (2016).
- 2 19. J. E. Bisanz, P. Soto-Perez, C. Noecker, A. A. Aksenov, K. N. Lam, G. E. Kenney, E. N.
3 Bess, H. J. Haiser, T. S. Kyaw, F. B. Yu, V. M. Rekdal, C. W. Y. Ha, S. Devkota, E. P.
4 Balskus, P. C. Dorrestein, E. Allen-Vercoe, P. J. Turnbaugh, A Genomic Toolkit for the
5 Mechanistic Dissection of Intractable Human Gut Bacteria. *Cell Host & Microbe* (2020), ,
6 doi:10.1016/j.chom.2020.04.006.
- 7 20. N. W. Palm, M. R. de Zoete, T. W. Cullen, N. A. Barry, J. Stefanowski, L. Hao, P. H.
8 Degnan, J. Hu, I. Peter, W. Zhang, E. Ruggiero, J. H. Cho, A. L. Goodman, R. A. Flavell,
9 Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease.
10 *Cell*. **158**, 1000–1010 (2014).
- 11 21. N. Koppel, J. E. Bisanz, M.-E. Pandelia, P. J. Turnbaugh, E. P. Balskus, Discovery and
12 characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of
13 a family of plant toxins. *Elife*. **7** (2018), doi:10.7554/eLife.33953.
- 14 22. Y. J. Weng, H. Y. Gan, X. Li, Y. Huang, Z. C. Li, H. M. Deng, S. Z. Chen, Y. Zhou, L. S.
15 Wang, Y. P. Han, Y. F. Tan, Y. J. Song, Z. M. Du, Y. Y. Liu, Y. Wang, N. Qin, Y. Bai, R.
16 F. Yang, Y. J. Bi, F. C. Zhi, Correlation of diet, microbiota and metabolite networks in
17 inflammatory bowel disease. *J. Dig. Dis.* **20**, 447–459 (2019).
- 18 23. H. B. Nielsen, M. Almeida, A. S. Juncker, S. Rasmussen, J. Li, S. Sunagawa, D. R. Plichta,
19 L. Gautier, A. G. Pedersen, E. Le Chatelier, E. Pelletier, I. Bonde, T. Nielsen, C.
20 Manichanh, M. Arumugam, J.-M. Batto, M. B. Quintanilha Dos Santos, N. Blom, N.
21 Borruel, K. S. Burgdorf, F. Boumezeur, F. Casellas, J. Doré, P. Dworzynski, F. Guarner,
22 T. Hansen, F. Hildebrand, R. S. Kaas, S. Kennedy, K. Kristiansen, J. R. Kultima, P.
23 Léonard, F. Levenez, O. Lund, B. Moumen, D. Le Paslier, N. Pons, O. Pedersen, E. Prifti, J.
24 Qin, J. Raes, S. Sørensen, J. Tap, S. Tims, D. W. Ussery, T. Yamada, MetaHIT Consortium,
25 P. Renault, T. Sicheritz-Ponten, P. Bork, J. Wang, S. Brunak, S. D. Ehrlich, MetaHIT
26 Consortium, Identification and assembly of genomes and genetic elements in complex
27 metagenomic samples without using reference genomes. *Nat. Biotechnol.* **32**, 822–828
28 (2014).
- 29 24. J. Qin, R. Li, J. Raes, M. Arumugam, K. S. Burgdorf, C. Manichanh, T. Nielsen, N. Pons, F.
30 Levenez, T. Yamada, D. R. Mende, J. Li, J. Xu, S. Li, D. Li, J. Cao, B. Wang, H. Liang, H.
31 Zheng, Y. Xie, J. Tap, P. Lepage, M. Bertalan, J.-M. Batto, T. Hansen, D. Le Paslier, A.
32 Linneberg, H. B. Nielsen, E. Pelletier, P. Renault, T. Sicheritz-Ponten, K. Turner, H. Zhu,
33 C. Yu, S. Li, M. Jian, Y. Zhou, Y. Li, X. Zhang, S. Li, N. Qin, H. Yang, J. Wang, S.
34 Brunak, J. Doré, F. Guarner, K. Kristiansen, O. Pedersen, J. Parkhill, J. Weissenbach,
35 MetaHIT Consortium, P. Bork, S. D. Ehrlich, J. Wang, A human gut microbial gene
36 catalogue established by metagenomic sequencing. *Nature*. **464**, 59–65 (2010).
- 37 25. Y. Guo, K. D. MacIsaac, Y. Chen, R. J. Miller, R. Jain, B. Joyce-Shaikh, H. Ferguson, I.-M.
38 Wang, R. Cristescu, J. Mudgett, L. Engstrom, K. J. Piers, G. A. Baltus, K. Barr, H. Zhang,
39 H. Mehmet, L. G. Hegde, X. Hu, L. L. Carter, T. D. Aicher, G. Glick, D. Zaller, A.
40 Hawwari, C. C. Correll, D. C. Jones, D. J. Cua, Inhibition of ROR γ T skews TCR α gene

- rearrangement and limits T cell repertoire diversity. *Cell Rep.* **17**, 3206–3218 (2016).
26. J. R. Huh, M. W. L. Leung, P. Huang, D. A. Ryan, M. R. Krout, R. R. V. Malapaka, J. Chow, N. Manel, M. Ciofani, S. V. Kim, A. Cuesta, F. R. Santori, J. J. Lafaille, H. E. Xu, D. Y. Gin, F. Rastinejad, D. R. Littman, Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR γ t activity. *Nature*. **472**, 486–490 (2011).
27. S. Fujita-Sato, S. Ito, T. Isobe, T. Ohyama, K. Wakabayashi, K. Morishita, O. Ando, F. Isono, Structural basis of digoxin that antagonizes ROR γ t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. *J. Biol. Chem.* **286**, 31409–31417 (2011).
28. M. S. Ladinsky, L. P. Araujo, X. Zhang, J. Veltri, M. Galan-Diez, S. Soualhi, C. Lee, K. Irie, E. Y. Pinker, S. Narushima, S. Bandyopadhyay, M. Nagayama, W. Elhenawy, B. K. Coombes, R. P. Ferraris, K. Honda, I. D. Iliev, N. Gao, P. J. Bjorkman, I. I. Ivanov, Endocytosis of commensal antigens by intestinal epithelial cells regulates mucosal T cell homeostasis. *Science*. **363** (2019), doi:10.1126/science.aat4042.
29. T. Sano, W. Huang, J. A. Hall, Y. Yang, A. Chen, S. J. Gavzy, J.-Y. Lee, J. W. Ziel, E. R. Miraldi, A. I. Domingos, R. Bonneau, D. R. Littman, An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. *Cell*. **163**, 381–393 (2015).
30. N. Geva-Zatorsky, E. Sefik, L. Kua, L. Pasman, T. G. Tan, A. Ortiz-Lopez, T. B. Yanortsang, L. Yang, R. Jupp, D. Mathis, C. Benoist, D. L. Kasper, Mining the human gut microbiota for immunomodulatory organisms. *Cell*. **168**, 928–943.e11 (2017).
31. A. N. Skelly, Y. Sato, S. Kearney, K. Honda, Mining the microbiota for microbial and metabolite-based immunotherapies. *Nat. Rev. Immunol.* **19**, 305–323 (2019).
32. J. R. Huh, D. R. Littman, Small molecule inhibitors of ROR γ t: targeting Th17 cells and other applications. *Eur. J. Immunol.* **42**, 2232–2237 (2012).
33. V. M. Buckalew, Endogenous digitalis-like factors: an overview of the history. *Front. Endocrinol.* **6**, 49 (2015).
34. S. Hang, D. Paik, L. Yao, E. Kim, T. Jamma, J. Lu, S. Ha, Bile acid metabolites control TH17 and T reg cell differentiation. *Nature*. **576**, 143–148 (2019).
35. V. Bronte, P. Zanovello, Regulation of immune responses by L-arginine metabolism. *Nat. Rev. Immunol.* **5**, 641–654 (2005).
36. L. A. Coburn, X. Gong, K. Singh, M. Asim, B. P. Scull, M. M. Allaman, C. S. Williams, M. J. Rosen, M. K. Washington, D. P. Barry, M. B. Piazuelo, R. A. Casero Jr, R. Chaturvedi, Z. Zhao, K. T. Wilson, L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. *PLoS One*. **7**, e33546 (2012).
37. M. Munder, K. Eichmann, M. Modolell, Alternative metabolic states in murine

- macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4⁺ T cells correlates with Th1/Th2 phenotype. *The Journal of Immunology*. **160**, 5347–5354 (1998).
38. L. A. J. O'Neill, R. J. Kishton, J. Rathmell, A guide to immunometabolism for immunologists. *Nat. Rev. Immunol.* **16**, 553–565 (2016).
39. R. Geiger, J. C. Rieckmann, T. Wolf, C. Basso, Y. Feng, T. Fuhrer, M. Kogadeeva, P. Picotti, F. Meissner, M. Mann, N. Zamboni, F. Sallusto, A. Lanzavecchia, L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. *Cell*. **167**, 829–842.e13 (2016).
40. T. S. Postler, S. Ghosh, Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. *Cell Metab.* **26**, 110–130 (2017).
41. B. Chassaing, J. D. Aitken, M. Malleshappa, M. Vijay-Kumar, Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr. Protoc. Immunol.* **104**, 15–25 (2014).
42. D. Aletaha, T. Neogi, A. J. Silman, J. Funovits, D. T. Felson, C. O. Bingham 3rd, N. S. Birnbaum, G. R. Burmester, V. P. Bykerk, M. D. Cohen, B. Combe, K. H. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J. M. Hazes, K. Hobbs, T. W. Huizinga, A. Kavanaugh, J. Kay, T. K. Kvien, T. Laing, P. Mease, H. A. Menard, L. W. Moreland, R. L. Naden, T. Pincus, J. S. Smolen, E. Stanislawski-Biernat, D. Symmons, P. P. Tak, K. S. Upchurch, J. Vencovsky, F. Wolfe, G. Hawker, 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* **62**, 2569–2581 (2010).
43. J. Bisanz, *LabProtocols* (Github; <https://github.com/jbisanz/LabProtocols>).
44. Q. Y. Ang, M. Alexander, J. C. Newman, Y. Tian, J. Cai, V. Upadhyay, J. A. Turnbaugh, E. Verdin, K. D. Hall, R. L. Leibel, E. Ravussin, M. Rosenbaum, A. D. Patterson, P. J. Turnbaugh, Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells. *Cell* (2020), doi:10.1016/j.cell.2020.04.027.
45. J. Szőköl, L. Rucká, M. Šimčíková, P. Halada, J. Nešvera, M. Pátek, Induction and carbon catabolite repression of phenol degradation genes in *Rhodococcus erythropolis* and *Rhodococcus jostii*. *Appl. Microbiol. Biotechnol.* **98**, 8267–8279 (2014).
46. K. Atarashi, T. Tanoue, T. Shima, A. Imaoka, T. Kuwahara, Y. Momose, G. Cheng, S. Yamasaki, T. Saito, Y. Ohba, T. Taniguchi, K. Takeda, S. Hori, I. I. Ivanov, Y. Umesaki, K. Itoh, K. Honda, Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science*. **331**, 337–341 (2011).
47. J. L. Round, S. M. Lee, J. Li, G. Tran, B. Jabri, T. A. Chatila, S. K. Mazmanian, The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science*. **332**, 974–977 (2011).
48. J. L. Kubinak, C. Petersen, W. Z. Stephens, R. Soto, E. Bake, R. M. O'Connell, J. L.

- 1 Round, MyD88 signaling in T cells directs IgA-mediated control of the microbiota to
2 promote health. *Cell Host Microbe*. **17**, 153–163 (2015).
- 3 49. *iggttools* (Github; <https://github.com/czbiohub/iggttools>).
- 4 50. `{{ngMeta['og:title']}}`, (available at <https://bio.tools/hs-blastn>).
- 5 51. ALDEx2. *Bioconductor*, (available at
6 <https://www.bioconductor.org/packages/release/bioc/html/ALDEx2.html>).
- 7 52. G. B. Gloor, J. M. Macklaim, V. Pawlowsky-Glahn, J. J. Egozcue, Microbiome Datasets
8 Are Compositional: And This Is Not Optional. *Frontiers in Microbiology*. **8** (2017), ,
9 doi:10.3389/fmicb.2017.02224.
- 10 53. A. D. Fernandes, J. N. Reid, J. M. Macklaim, T. A. McMurrough, D. R. Edgell, G. B.
11 Gloor, Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-
12 seq, 16S rRNA gene sequencing and selective growth experiments by compositional data
13 analysis. *Microbiome*. **2**, 15 (2014).
- 14 54. A. D. Fernandes, J. M. Macklaim, T. G. Linn, G. Reid, G. B. Gloor, ANOVA-like
15 differential expression (ALDEx) analysis for mixed population RNA-Seq. *PLoS One*. **8**,
16 e67019 (2013).
- 17 55. S. Nayfach, B. Rodriguez-Mueller, N. Garud, K. S. Pollard, An integrated metagenomics
18 pipeline for strain profiling reveals novel patterns of bacterial transmission and
19 biogeography. *Genome Res*. **26**, 1612–1625 (2016).
- 20 56. *iggttools* (Github; <https://github.com/czbiohub/iggttools>).
- 21 57. A. Almeida, S. Nayfach, M. Boland, F. Strozzi, M. Beracochea, Z. J. Shi, K. S. Pollard, D.
22 H. Parks, P. Hugenholtz, N. Segata, N. C. Kyrpides, R. D. Finn, A unified sequence
23 catalogue of over 280,000 genomes obtained from the human gut microbiome. *bioRxiv*
24 (2019), p. 762682.
- 25 58. ElenMatchR: Comparative Genomics Tool v1.0.9001, (available at
26 <https://jbisanz.shinyapps.io/elenmatchr/>).

27

28 **Acknowledgments:** We acknowledge the UCSF gnotobiotic core (Jessie Turnbaugh, Kimberly
29 Ly, Jolie Ma, Greg Ostolaza) for help with designing and execution of gnotobiotic experiments;
30 Jody Baron and Jillian Jespersen for the *Rorc*^{-/-} mice; Emily Balskus, Vayu Maini Rekdal, and
31 Nitzan Koppel for the Cgr2 WT and Y333N plasmids and *R. erythropolis*; and Chunyu Zhao for

assistance with MIDAS and IGGtools troubleshooting. We acknowledge the PFCC for assistance generating flow cytometry data (NIH P30 DK063720) and the UCSF Biorepository and Tissue Biomarker Technology Core for assistance with histology. We would also like to thank Kathy Lam, Tiffany Scharschmidt, and Mark Ansel for their critical reading and feedback on the manuscript. The model figure in S10 was made using BioRender.com software. **Funding:** This work was supported by the National Institutes of Health [R01HL122593, R21CA227232, R01AR074500, R01DK114034 (P.J.T.); 5T32AI060537, F32AI147456-01 (M.A.); 5T32AR007304-37, TR001871, K08AR073930 (R.N.)], the Searle Scholars Program (SSP-2016-1352), MedImmune, and the Breakthrough Program for Rheumatoid-related Arthritis Research (with the support of the UCSF Program for Breakthrough Biomedical Research). P.J.T. is a Chan Zuckerberg Biohub investigator and was a Nadia's Gift Foundation Innovator supported, in part, by the Damon Runyon Cancer Research Foundation (DRR-42-16). **Author contributions:** Conceptualization, M.A. and P.J.T.; Investigation, M.A., Q.Y.A., R.R.N., V.U. A.E.B.; Resources, P.J.T.; Writing – Original Draft, M.A.; Writing – Review and Editing, M.A., Q.Y.A., R.R.N., V.U., P.J.T.; Supervision, P.J.T. K.S.P. **Competing interests:** P.J.T. is on the scientific advisory board for Kaleido, Pendulum, Seres, and SNIPRbiome. This work was partially supported by a research grant from MedImmune, Inc. **Data and materials availability:** All data is available in the main text or the supplementary materials.

Supplementary Materials:

Materials and Methods

Figs. S1 to S10

Tables S1 to S2

Captions for Data S1 and S2

Other Supplementary Materials for this manuscript include the following:

Data S1 to S2 [DSS disease scores, Reagents]

Figure Legends

Fig. 1. *E. lenta* colonization increases intestinal CD4⁺ IL-17a⁺ cells in the presence and absence of an intact gut microbiota. (A-F) IL-17a⁺ CD4⁺ Th17 levels within the CD3⁺ population and IL-17a mean fluorescence intensity (MFI) were measured via flow cytometry in the small intestinal and colonic lamina propria of germ-free (GF) mice or mice monocolonized with *E. lenta* strain UCSF 2243 for two weeks (n=8-10). Representative flow plots of the IL-17a⁺ CD4⁺ population within the CD3⁺ gate are displayed and fold changes (relative to GF) of this population and IL-17a MFI are quantified to the right. Data are pooled from two independent experiments with each point representing an individual mouse. (G-L) Representative flow and fold change (relative to GF) of CD4⁺ Rorγt⁺ cells within the CD3⁺ population and MFI of Rorγt in the small intestinal and colonic lamina propria from the same mice in A-F. (M) RT-qPCR panel of immune genes from GF or *E. lenta* monocolonized ileal samples (n=10-16). Data are relative to GF. (N-S) C57BL/6J SPF mice were gavaged every other day for 2 weeks with BHI media control or *E. lenta* strain 2243 (n=10-11). Representative flow plots of (N) small intestinal and (Q) colonic lamina propria IL-17a⁺ CD4⁺ cells within the CD3⁺ population and fold change of this population and IL-17a MFI are plotted to the right. Data are from three independent experiments. Each point represents an individual mouse and the mean±SEM is plotted. **P* < 0.05; ***P* < 0.01; or listed, Welch's t-test. See figs. S1, S2, and S3 for gating strategy and additional related data.

Fig. 2. *E. lenta* colonization contributes to worsened colitis in a Rorc-dependent manner. (A-D) Germ-free (GF) or *E. lenta* strain 2243 monocolonized mice were treated with 2% DSS for 6

days and (A) disease was scored based on published scoring metrics (41). *** $P < 0.001$ two-way ANOVA with Sidak's multiple comparison correction. Data are from 2 independent experiments (n=7-8). (B) Colon shortening was assayed and relative colon length is displayed (relative to GF). **** $P < 0.0001$ (Welch's t-test). (C) Representative histology from GF or *E. lenta* monocolonized colons with H&E staining at 10X magnification. (D) Relative lipocalin levels as measured via ELISA from the colon content. ** $P < 0.01$ (Welch's t-test) (E-H) SPF WT or *Rorc*^{-/-} mice were gavaged with a BHI media control or *E. lenta* 2243 every other day for 2 weeks then treated with 2% DSS for 7 days and disease was tracked. (E) Disease scores over time in WT SPF mice treated with BHI or *E. lenta*. * $P < 0.05$, *** $P < 0.001$ two-way ANOVA with Sidak's multiple comparison correction (n=4). (F) Day 7 colon lengths in the same mice as E. (G) Disease scores over time in *Rorc*^{-/-} SPF mice treated with BHI or *E. lenta*. (H) Day 7 colon lengths in the same mice as G. P value stated in Welch's t-test. Data are from 1 representative experiment. (I-K) *IL-10*^{-/-} mice were gavaged with a BHI media control or *E. lenta* 2243 three times a week for 6 weeks and (I) percentage of initial weight was tracked (n=11). * $P < 0.05$ two-way ANOVA with Sidak's multiple comparison correction. Mice that dropped out of the study before week 4 were removed from weight change analysis. (J) Percent survival of *IL-10*^{-/-} mice gavaged with BHI or *E. lenta* 2243 three times a week for 10 weeks (n=19 (BHI) 26 (*E. lenta*)). Mice were sacrificed when rectal prolapse developed. Data are from 2 independent experiments. * $P < 0.05$ Log-rank Mantel-Cox test. (K) Lipocalin levels were measured via ELISA from the colon content after 6-10 weeks of gavage. * $P < 0.05$ (Welch's t-test). Data are from 2 independent experiments and set relative to BHI (n=11). Mean±SEM is displayed. Each dot represents an individual mouse. See also fig. S5 and data S1 for related data.

Fig. 3. Th17 accumulation and colitis severity varies between *E. lenta* strains. (A-D) Th17 levels were analyzed in germ-free (GF) mice or mice monocolonized with *E. lenta* 2243 (2243), *E. lenta* 1356 (1356), *E. lenta* 15644 (15644), or *E. lenta* AB12#2 (AB12) as measured by IL-17a+ CD4+ within the live TCRb+ population in the (A-B) small intestinal and (C-D) colonic lamina propria. Representative flow plots are shown and fold change compared to the GF group is quantified to the right. Data are from 2 independent experiments (n=8-11). (E-I) GF, mice or monocolonized with *E. lenta* 2243, or *E. lenta* 1356 for 2 weeks were treated with 2% DSS and (E) disease was tracked for 7 days (n=8-10). *** $P < 0.001$; **** $P < 0.0001$ two-way ANOVA with Sidak's multiple comparison correction. (F) Day 7 colon lengths. (G) Lipocalin levels as quantified via ELISA in the colon content. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ (one-way ANOVA with Tukey multiple comparison test unless otherwise noted). Mean±SEM is displayed. Each dot represents an individual mouse. See figs. S3 for gating strategies and S6, table S1, and Data S1 for related data.

Fig. 4. A single strain-variable genomic locus is predictive and sufficient for IL-17a induction. (A) Splenic T cells were treated with Th17 skewing conditions and conditioned media from *E. lenta* strains (2243, 1356, or 15644), a BHI media control, or no treatment (NS). IL-17a levels in the supernatant were measured via ELISA after 4 days of skewing followed by overnight PMA ionomycin restimulation (n=18-20 biological replicates (wells)/group). Levels of IL-17a are relative to the no treatment control which is set to 1. (B) In the same experimental design as A, 10 strains of *E. lenta* were screened and levels of IL-17a are relative to the no treatment control which is set to 1. Strains were classified into non-IL-17a inducers (fold IL-17a levels below 1) or high (fold IL-17a levels above 1). With these classifications we performed comparative genomics using

1 ElenMatchR with 80% coverage and 80% minimum identity (19) to determine genomic regions
2 shared between the 4 inducing strains and absent from the 6 non-inducing strains (n=8-12
3 biological replicates (wells)/group). Feature ID numbers 2770-2839 correspond to the cardiac
4 glycoside reductase (*cgr*)-associated gene cluster (21) which is highlighted by the red box. (C)
5 With our *in vitro* Th17 system we tested *Rhodococcus erythropolis* strains with induced
6 (+Thiostrepton) or uninduced (-Thiostrepton) expression of WT Cgr2 (n=14), a natural partial
7 loss-of-function variant Y333N Cgr2 (n=12) with no treatment (NS) (n = 14), BHI (+/-
8 Thiostrepton) (n=12 and n=8) as controls. Levels of IL-17a are relative to the no treatment control.
9 ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$ Welch's t-test. (D-E) C57BL/6J SPF mice were
10 gavaged with conditioned media from *R. erythropolis* strains with induced (+Thiostrepton) or
11 uninduced (-Thiostrepton) expression of WT Cgr2, Y333N Cgr2, or a BHI media control (with
12 Thiostrepton). Representative flow plots of CD4⁺ IL-17a⁺ within the live CD3⁺ population in the
13 small intestinal lamina propria lymphocytes are displayed and fold change relative to the BHI
14 group quantified to the right (n=10). Each point represents an individual mouse. Data represents a
15 combination of at least two independent experiments for A-E. (F) Relative levels of *cgr2* as
16 measured via qRT-PCR from fecal samples from rheumatoid arthritis (RA) patients or healthy
17 controls before therapeutic intervention and normalized for input mg of sample. Levels are relative
18 to the healthy group (n=11-12). * $P < 0.05$ (Mann-Whitney test). (G) The percentage of RA or
19 healthy stool samples with detectable *cgr2*. Numbers listed are number positive over total samples
20 in the group. Mean±SEM is displayed. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$
21 (one-way ANOVA with Tukey multiple comparison test unless otherwise noted). Mean±SEM is
22 displayed. Each dot represents an individual mouse or human. See table S1 for strain metadata.

Raw values for IL-17a ELISA can be found in table S2. See figs. S3 for gating strategies and S7 and S8 for related data.

Fig. 5. A high arginine diet inhibits Th17 accumulation and colitis induction by a *cgr*⁺ *E. lenta* strain.

(A-B) Mice on a 1% or 3% arginine diet either remained germ-free (GF) or were monocolonized with *E. lenta* 2243 (2243) or *E. lenta* 15644 (15644) for 2 weeks. (A) Representative flow plots of Th17 (CD4⁺ IL-17a⁺ cells within the live CD3⁺ population) from the small intestinal lamina propria and the fold change of this population relative to the GF 1% arginine is quantified (B). Data are from 2 independent experiments (n=8-11). (C-G) SPF mice on a 1% or 3% arginine (Arg) diet were gavaged every other day with BHI, *E. lenta* 2243, or *E. lenta* 15644 for two weeks and then 2% DSS was administered and (C) disease scores were tracked for 7 days. ***P* < 0.01 two-way ANOVA with Sidak's multiple comparison correction (1% vs. 3% 2243). (n=5-10). (D) Relative colon lengths of SPF gavaged with BHI, *E. lenta* 2243 or 1356 on a 1% or 3% Arg diet given 2% DSS. (E) Relative lipocalin in the colon content from the same mice as in (D). Data are from 2 independent experiments and set relative to the 15644 group on the 1% Arg diet which is set to 1. (F-G) Representative flow and percentages of IL-17a⁺ CD4⁺ cells within the live CD3⁺ population from the small intestinal lamina propria. **P* < 0.05; ***P* < 0.01; ****P* < 0.001; *****P* < 0.0001 or stated (one-way ANOVA with Tukey multiple comparison test unless otherwise stated). Mean±SEM is displayed. Each point represents an individual mouse. See figs. S3 for gating strategies and S9 for related data.

A

B

C

D

E

F

G

H

I

J

K

A

B

C

Small Intestine
Gated on live CD3+ cells

D

E

F

G

A

Small Intestine
Gated on live CD3+ cells

B

C

D

E

F

Small Intestine
Gated on live CD3+ cells

G